Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

1.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Bibliometric Analysis of Pharmacist-Delivered Care: Global Trends, Outcomes, and Practice Settings (2000-2024).

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Future-Proofing Pharmacy: A Stakeholder-Informed Forecast of Workforce and Education Needs.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Utilization of Provider-Patient Communication Tools and Approaches to Facilitate Vaccine Confidence: A Systematic Review.

Vaccines·2025
Same author

Developing pharmacists as researchers through education, practice, and collaboration: a case-based report from a US college of pharmacy.

The International journal of pharmacy practice·2025
Same author

The Safety and Efficacy of Glucosamine and/or Chondroitin in Humans: A Systematic Review.

Nutrients·2025
Same author

Moving upstream: The need for pharmacists to address food security.

Journal of the American Pharmacists Association : JAPhA·2025

Related Experiment Video

Updated: Jun 11, 2025

Profiling of Methyltransferases and Other S-adenosyl-L-homocysteine-binding Proteins by Capture Compound Mass Spectrometry CCMS
17:12

Profiling of Methyltransferases and Other S-adenosyl-L-homocysteine-binding Proteins by Capture Compound Mass Spectrometry CCMS

Published on: December 20, 2010

15.6K

S-Adenosylmethionine (SAMe) for Central Nervous System Health: A Systematic Review.

Kyrie Eleyson R Baden1, Halley McClain1, Eliya Craig1

  • 1School of Pharmacy, Cedarville University, Cedarville, OH 45314, USA.

Nutrients
|September 28, 2024
PubMed
Summary

S-adenosylmethionine (SAMe) shows promise for improving mood and other central nervous system (CNS) signs. This systematic review found SAMe effective in most studies, with mild side effects, but more research on long-term CNS effects is needed.

Keywords:
S-adenosylmethioninecentral nervous system

More Related Videos

Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods
10:24

Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods

Published on: November 19, 2019

13.5K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K

Related Experiment Videos

Last Updated: Jun 11, 2025

Profiling of Methyltransferases and Other S-adenosyl-L-homocysteine-binding Proteins by Capture Compound Mass Spectrometry CCMS
17:12

Profiling of Methyltransferases and Other S-adenosyl-L-homocysteine-binding Proteins by Capture Compound Mass Spectrometry CCMS

Published on: December 20, 2010

15.6K
Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods
10:24

Simultaneous Flow Cytometric Characterization of Multiple Cell Types Retrieved from Mouse Brain/Spinal Cord Through Different Homogenization Methods

Published on: November 19, 2019

13.5K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • S-adenosylmethionine (SAMe) is a naturally occurring compound investigated for its potential to alleviate mood-related symptoms.
  • Central Nervous System (CNS) signs, including mood, behavior, and sleep disturbances, are common targets for therapeutic interventions.

Purpose of the Study:

  • To systematically evaluate the efficacy and safety of S-adenosylmethionine (SAMe) for improving Central Nervous System (CNS) signs.
  • To identify the optimal dosage of SAMe for CNS-related symptom management.
  • To synthesize findings from existing research on SAMe's impact on mood, behavior, and sleep.

Main Methods:

  • A PRISMA-based systematic review was performed, searching major databases (PubMed, CINAHL, Web of Science) using Medical Subject Headings (MeSH) terms.
  • Independent review of articles by two researchers, with a third resolving discrepancies, was conducted during title/abstract screening and full-text evaluation.
  • Data extraction and quality assessment of included studies were performed systematically to ensure reliability.

Main Results:

  • Out of 1881 initial studies, 36 high-quality studies focusing on CNS signs were included in the review.
  • S-adenosylmethionine (SAMe) demonstrated effectiveness in 24 out of 36 reviewed studies.
  • Adverse events associated with SAMe were predominantly mild and transient gastrointestinal disturbances.

Conclusions:

  • A significant number of patients experienced improvements in Central Nervous System (CNS) signs when treated with S-adenosylmethionine (SAMe), either as a standalone therapy or adjunctively.
  • The findings support the potential utility of SAMe in managing mood, behavior, and sleep disturbances.
  • Further research is warranted to elucidate the long-term effects and optimal application of SAMe within the Central Nervous System (CNS).